And the winner in life sciences reliability and compatibility is…PCI Synthesis


Newburyport, Mass., Feb. 9, 2016 – PCI Synthesis, Inc. (, a drug substance manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), today announced that it has been recognized as a Life Science Leader CMO Leadership Award recipient in the categories of Reliability (small pharma) and Compatibility (small pharma).

This is the third consecutive year that PCI Synthesis has been awarded multiple CMO Leadership Awards and the company has now won an award in all five major category in which the awards are given, including Quality, Innovation, Productivity, Reliability and Compatibility.

The awards will be presented at the CMO Leadership Awards Ceremony and Reception at the W Hotel on Wednesday, March 16, 2016 in NYC.

“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” said Louis Garguilo, Executive Editor, Life Science Leader magazine and “Recipients are evaluated by executives and managers of the CMO’s sponsors, in the 5 critical categories of capabilities, compatibility, expertise, quality, and reliability. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”

To determine this year’s winners, Life Science Leader teamed up with Industry Standard Research (ISR). More than 80 contract manufacturers were considered. The annual awards recognize those contract manufacturing organizations (CMOs) that are the most highly rated using an assessment of 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents include decision-makers at pharma and biopharma companies of all sizes, who evaluate only those companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with contract manufacturers and clear experiential data.

“Winning across multiple categories of this prestigious award for the last three years validates our approach to the business. At PCI Synthesis, we work hard both on the science in the labs and on the relationships across the table with our customers. We see ourselves as part of their team, and we seek to provide value to every project,” said Ed Price, president and CEO of PCI Synthesis. “We focus on communication with our customers, make and keep our commitment to top quality and our investment in best practices to show our value.”

PCI, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, recently announced that its commercially approved products portfolio now includes nine commercial products that either have or are imminently receiving FDA approval for sale in the U.S. The company has more than 17 API and other advanced materials products in its pipeline.

About PCI Synthesis

PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit